July 18, 2012
MENLO PARK, Calif., July 18, 2012 - Exponent, Inc. (Nasdaq: EXPO) today reported financial results for the second quarter and six months ended June 29, 2012.
For the second quarter of 2012, total revenues increased 14% to $74,484,000, as compared to $65,106,000 in the same period one year ago. Revenues before reimbursements increased 13% to $68,318,000, as compared to $60,573,000 in the second quarter of 2011.
Net income for the quarter increased 26% to $10,327,000, or $0.72 per diluted share, as compared to $8,217,000, or $0.55 per diluted share, reported in the same quarter a year ago. EBITDA1 improved 22% to $18,342,000, as compared to $14,987,000 in the second quarter last year.
For the first half of 2012, total revenues increased 6% to $146,409,000, as compared to $138,579,000 in the same period of last year. Revenues before reimbursements increased 8% to $134,788,000, as compared to $124,756,000, in the same period of 2011.
Net income for the first half of 2012 increased 14% to $18,528,000, or $1.29 per diluted share, as compared to $16,220,000, or $1.08 per diluted share, reported in the prior year period. EBITDA1 in the first half of 2012 improved 13% to $33,142,000, as compared to $29,409,000, in the first half of 2011.
During the second quarter of 2012, Exponent repurchased $14.4 million of its common stock, and closed the quarter with $109.0 million in cash, cash equivalents and short-term investments.
“We are pleased with our second quarter performance having produced double-digit revenue growth and increased profitability,” commented Dr. Paul Johnston, President and CEO. “We continued to benefit from strong demand across a broad range of our services, both proactive and reactive. We experienced high utilization as we continued to benefit from new work in key areas as well as a few major projects. In our environmental and health segment we had notable contributions from our environmental sciences, ecological sciences, chemical registration and food safety, and exposure assessment practices. In our engineering and other scientific segment we had notable performances from our mechanics and materials, electrical, biomedical, vehicle, and engineering management consulting practices. In addition, our defense technology development business saw an increase in activity supporting the U.S. Army’s Rapid Equipping Force which was offset by the winding down of our current U.S. ground penetrating radar development contract.
“For the full year 2012, we are increasing our outlook for growth in revenue before reimbursements to be in the mid-single digits and expect full year EBITDA1 margin to be approximately flat over the prior year. This outlook reflects the strong utilization during the first half of the year, our expectation that a few major projects will step down in their level of activity in the next several quarters, and lower defense technology development product sales as compared to the prior year. We are pleased with our performance to date and are optimistic about our ability to weather a difficult economic environment as our project work, both in the U.S. and internationally, are in areas that we believe are less sensitive to the economic slowdown. We look forward to further translating our unique scientific and engineering capabilities into additional shareholder value over time,” concluded Dr. Johnston.
Financial Tables for Quarter-Ending June 29, 2012
Today's Conference Call Information
Exponent will discuss its financial results in more detail on a conference call today, July 18, 2012, starting at 4:30 p.m. Eastern Time/1:30 p.m. Pacific Time. The audio on the conference call is available by dialing 877-941-2068 or 480-629-9712. A live webcast of the call will be available on the Investor Relations section of the Company's website at www.exponent.com/investors. For those unable to listen to the live webcast, a replay of the call will also be available on the Exponent web site, or by dialing 800-406-7325 or 303-590-3030, and entering reservation 4551395#.
Exponent is an engineering and scientific consulting firm providing solutions to complex problems. Exponent's multidisciplinary organization of scientists, physicians, engineers, and business consultants brings together more than 90 technical disciplines to address complicated issues facing industry and government today. The firm has been best known for analyzing accidents and failures to determine their causes, but in recent years it has become more active in assisting clients with human health, environmental and engineering issues associated with new products to help prevent problems in the future.
Exponent may be reached at (888) 656-EXPO, firstname.lastname@example.org, or www.exponent.com.
This news release contains, and incorporates by reference, certain "forward-looking" statements (as such term is defined in the Private Securities Litigation Reform Act of 1995, and the rules promulgated pursuant to the Securities Act of 1933, as amended, and the Securities Exchange Act of 1934, as amended thereto under) that are based on the beliefs of the Company's management, as well as assumptions made by and information currently available to the Company's management. Such forward-looking statements are subject to the safe harbor created by the Private Securities Litigation Reform Act of 1995. When used in this document and in the documents incorporated herein by reference, the words "anticipate," "believe," "estimate," "expect" and similar expressions, as they relate to the Company or its management, identify such forward-looking statements. Such statements reflect the current views of the Company or its management with respect to future events and are subject to certain risks, uncertainties and assumptions. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, the Company's actual results, performance, or achievements could differ materially from those expressed in, or implied by, any such forward-looking statements. Factors that could cause or contribute to such material differences include the possibility that the demand for our services may decline as a result of changes in general and industry specific economic conditions, the timing of engagements for our services, the effects of competitive services and pricing, the absence of backlog related to our business, our ability to attract and retain key employees, the effect of tort reform and government regulation on our business, and liabilities resulting from claims made against us. Additional risks and uncertainties are discussed in our Annual Report on Form 10-K under the heading "Risk Factors" and elsewhere in the report. The inclusion of such forward-looking information should not be regarded as a representation by the Company or any other person that the future events, plans, or expectations contemplated by the Company will be achieved. The Company undertakes no obligation to release publicly any updates or revisions to any such forward-looking statements.
1 EBITDA is a non-GAAP financial measure defined by the Company as net income before income taxes, interest income, depreciation and amortization. EBITDAS is a non-GAAP financial measure defined by the Company as EBITDA before stock-based compensation. The Company regards EBITDA and EBITDAS as useful measures of operating performance and cash flow to complement operating income, net income and other GAAP financial performance measures. Additionally, management believes that EBITDA and EBITDAS provide meaningful comparisons of past, present and future operating results. Generally, a non-GAAP financial measure is a numerical measure of a company's performance, financial position or cash flow that either excludes or includes amounts that are not normally excluded or included in the most directly comparable measure calculated and presented in accordance with GAAP. These measures, however, should be considered in addition to, and not as a substitute or superior to, operating income, cash flows, or other measures of financial performance prepared in accordance with GAAP. A reconciliation of the measures to GAAP is set forth below.